


What is claimed is:

1. A compound of Formula (I):



or a pharmaceutically acceptable salt thereof, wherein:

Q is selected from N and CH;

Ring A is 4- to 15-membered heterocyclyl substituted with 1-4 R₇;

R₁ is selected from CH₃, CD₃, and -CH₂-5 membered heterocyclyl comprising carbon atoms and 1-3 heteroatoms selected from N, NC₁₋₄alkyl, O, and S;

R₂ is selected from H, C₁₋₃ alkyl substituted with 0-5 R_e, and -(CH₂)_r-C₃₋₆ cycloalkyl substituted with 0-5 R_e;

R₃ is selected from H, F, Cl, Br, -OR_b, and C₁₋₃ alkyl substituted with 0-5 R_e;

L is absent or selected from -NR_d-, -O-, -C(=O)NR_d-, and -S(O)_p-;

R₄ is selected from -(CH₂)_r-aryl substituted with 1-7 R₅, -(CH₂)_r-C₃₋₁₂ cycloalkyl (substituted with 1-2 OR_b, C(=O)OR_b, -C(=O)NR_aR_a, -NR_aC(=O)R_b), -(CH₂)_r-heterocyclyl comprising carbon atoms and 1-3 heteroatoms selected from N, NR₆, O, and S and substituted with 1-7 R₅;

R₅, at each occurrence, is independently selected from H, F, Cl, Br, CN, =O, nitro, C₁₋₄alkyl substituted with 0-5 R_e, C₂₋₄alkenyl substituted with 0-5 R_e, C₂₋₄alkynyl substituted with 0-5 R_e, -(CHR_d)_rOR_b, - (CHR_d)_rS(O)_pR_c, -(CHR_d)_rS(O)_pNR_aR_a, -(CHR_d)_rNR_aS(O)_pR_c, -(CHR_d)_rNR_aR_a, - (CHR_d)_rNR_aC(=O)R_b, -(CHR_d)_rNR_aC(=O)OR_b, - (CHR_d)_rNR_aC(=O)NR_aR_a, -(CHR_d)_rC(=O)R_b, -(CHR_d)_rC(=O)OR_b, - (CHR_d)_rC(=O)NR_aR_a, -(CHR_d)_rOC(=O)R_b, -(CHR_d)_rOC(=O)OR_b, - (CHR_d)_rO(CH₂)_rC(=O)NR_aR_a, C₃₋₆cycloalkyl substituted with 0-4 R_e, aryl substituted with 0-4 R_e, and heterocyclyl substituted with 0-4 R_e;

R₆ is selected from H, C₁₋₃alkyl substituted with 0-4 R_e, -

S(O)_pR_c, -(CH₂)_rC(=O)R_b, -(CH₂)_rC(=O)OR_b, -(CH₂)_rC(=O)(CH₂)_rNR_aR_a, -
C(=O)(CH₂)_rNR_aC(=O)R_b,

-S(O)_pNR_aR_a, -(CH₂)_r-C₃₋₆cycloalkyl substituted with 0-4 R_e, -(CH₂)_r-aryl substituted with
0-4 R_e, and -(CH₂)_r-heterocyclyl substituted with 0-4 R_e;

R₇ is selected from H, F, Cl, CN, C₁₋₃ alkyl, =N-OR_b, -(CH₂)_rOR_b, -(CH₂)_rNR_aR_a, -
NR_aC(=NH)C₁₋₃alkyl, -NR_aC(=O)OR_b, carbocycle, and heterocycle;
alternatively, two R₇ groups are taken together to form carbocyclyl or
heterocyclyl;

R₈, at each occurrence, is independently selected from H, F, Cl, Br, and C₁₋₄alkyl
substituted with 0-5 R_e;

R_a, at each occurrence, is independently selected from H, C₁₋₆ alkyl substituted with 0-5
R_e, C₂₋₆ alkenyl substituted with 0-5 R_e, C₂₋₆ alkynyl substituted with 0-5 R_e, -
(CH₂)_r-C₃₋₁₀carbocyclyl substituted with 0-5 R_e, and -(CH₂)_r-heterocyclyl
substituted with 0-5 R_e; or R_a and R_a together with the nitrogen atom to which
they are both attached form a heterocyclic ring substituted with 0-5 R_e;

R_b, at each occurrence, is independently selected from H, C₁₋₆ alkyl substituted with 0-5
R_e, C₂₋₆ alkenyl substituted with 0-5 R_e, C₂₋₆ alkynyl substituted with 0-5
R_e, -(CH₂)_r-C₃₋₁₀carbocyclyl substituted with 0-5 R_e, and -(CH₂)_r-heterocyclyl
substituted with 0-5 R_e;






R_c, at each occurrence, is independently selected from C₁₋₆ alkyl substituted with 0-5 R_e,
C₂₋₆alkenyl substituted with 0-5 R_e, C₂₋₆ alkynyl substituted with 0-5 R_e, -(CH₂)_r-
C₃₋₆ carbocyclyl substituted with 0-5 R_e, and -(CH₂)_r-heterocyclyl substituted with
0-5 R_e;

R_d, at each occurrence, is independently selected from H, C₁₋₆ alkyl substituted with 0-5
R_e, and OH,


R_e, at each occurrence, is independently selected from C₁₋₆ alkyl substituted with 0-5 R_f,
C₂₋₆ alkenyl, C₂₋₆ alkynyl, -(CH₂)_r-C₃₋₆
cycloalkyl, -(CH₂)_r-aryl, -(CH₂)_r-heterocyclyl, Si(C₁₋₄alkyl)₃, F, Cl, Br, CN, NO₂,
=O, CO₂H, -(CH₂)_rOR_f, S(O)_pR_f, C(=O)NR_fR_f, S(O)_pNR_fR_f, and -(CH₂)_rNR_fR_f;

R_f, at each occurrence, is independently selected from H, F, Cl, Br, CN, OH, C₁₋₅ alkyl
optionally substituted with OH, C₂₋₅ alkenyl, C₂₋₅ alkynyl, C₃₋₆ cycloalkyl, and

phenyl, or R_f and R_f together with the nitrogen atom to which they are both attached form a heterocyclic ring optionally substituted with C_{1-4} alkyl;
 p , at each occurrence, is independently selected from zero, 1, and 2;
 r , at each occurrence, is independently selected from zero, 1, 2, 3, and 4;
provided:

- (1) when L is absent, R_4 is not , , and ;
(2) when L is $-NR_d-$, R_4 is not , and ; and
(3) when L is $-O-$, R_4 is not C_{3-6} cycloalkyl.

2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein:





R_1 is selected from CH_3 and CD_3 ;


R_2 is selected from methyl, ethyl and $-CH_2$ -cyclopropyl substituted with 0-3 R_e ;


R_3 is selected from H, F, Cl, Br, and $-OC_{1-4}$ alkyl;

L is absent or selected from $-NR_d-$, $-O-$, $-C(=O)NH-$, $-S-$, and $-S(O)_2-$;










$(\text{CH}_2)_r\text{S}(\text{O})_p\text{R}_c$, $-(\text{CH}_2)_r\text{S}(\text{O})_p\text{NR}_a\text{R}_a$, $-(\text{CH}_2)_r\text{NR}_a\text{S}(\text{O})_p\text{R}_c$, $-(\text{CH}_2)_r\text{NR}_a\text{R}_a$, -
 $(\text{CH}_2)_r\text{NR}_a\text{C}(=\text{O})\text{R}_b$, $-(\text{CH}_2)_r\text{NR}_a\text{C}(=\text{O})\text{OR}_b$, -
 $(\text{CH}_2)_r\text{NR}_a\text{C}(=\text{O})\text{NR}_a\text{R}_a$, $-(\text{CH}_2)_r\text{C}(=\text{O})\text{R}_b$, $-(\text{CH}_2)_r\text{C}(=\text{O})\text{OR}_b$, -
 $(\text{CHR}_d)_r\text{C}(=\text{O})\text{NR}_a\text{R}_a$, $-(\text{CH}_2)_r\text{OC}(=\text{O})\text{R}_b$, $-(\text{CH}_2)_r\text{OC}(=\text{O})\text{OR}_b$, $-(\text{CH}_2)_r$
 $\text{O}(\text{CH}_2)_r\text{C}(=\text{O})\text{NR}_a\text{R}_a$, C_{3-6} cycloalkyl substituted with 0-4 R_e , aryl substituted with
0-4 R_e , and heterocyclyl substituted with 0-4 R_e ;
 R_6 , at each occurrence, is independently selected from H, C_{1-3} alkyl substituted with 0-4
 R_e , $-\text{S}(\text{O})_p\text{R}_c$, $-\text{C}(=\text{O})\text{R}_b$, $-(\text{CH}_2)_r\text{C}(=\text{O})\text{OR}_b$, $-(\text{CH}_2)_r\text{C}(=\text{O})(\text{CH}_2)_r\text{NR}_a\text{R}_a$, -
 $\text{C}(=\text{O})(\text{CH}_2)_r\text{NR}_a\text{C}(=\text{O})\text{R}_b$, $-\text{S}(\text{O})_p\text{NR}_a\text{R}_a$, $-(\text{CH}_2)_r$ -aryl substituted with 0-4 R_e ,
and $-(\text{CH}_2)_r$ -heterocyclyl substituted with 0-4 R_e ;
 R_a , at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5
 R_e , C_{2-6} alkenyl substituted with 0-5 R_e , C_{2-6} alkynyl substituted with 0-5 R_e , -
 $(\text{CH}_2)_r$ - C_{3-10} carbocyclyl substituted with 0-5 R_e , and $-(\text{CH}_2)_r$ -heterocyclyl
substituted with 0-5 R_e ; or R_a and R_a together with the nitrogen atom to which
they are both attached form a heterocyclic ring substituted with 0-5 R_e ;
 R_b , at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5
 R_e , C_{2-6} alkenyl substituted with 0-5 R_e , C_{2-6} alkynyl substituted with 0-5 R_e , -
 $(\text{CH}_2)_r$ - C_{3-10} carbocyclyl substituted with 0-5 R_e , and $-(\text{CH}_2)_r$ -heterocyclyl
substituted with 0-5 R_e ;
 R_c , at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_e ,
 C_{2-6} alkenyl substituted with 0-5 R_e , C_{2-6} alkynyl substituted with 0-5 R_e , $-(\text{CH}_2)_r$ -
 C_{3-6} carbocyclyl substituted with 0-5 R_e , and $-(\text{CH}_2)_r$ -heterocyclyl substituted with
0-5 R_e ;
 R_d , at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5
 R_e , and OH;
 R_e , at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_f ,
 C_{2-6} alkenyl, C_{2-6} alkynyl, $-(\text{CH}_2)_r$ - C_{3-6}
cycloalkyl, $-(\text{CH}_2)_r$ -aryl, $-(\text{CH}_2)_r$ -heterocyclyl, F, Cl, Br, CN, NO_2 , $=\text{O}$, $-\text{NH}_2$, -
 NHC_{1-4} alkyl, $-\text{N}(\text{C}_{1-4}\text{alkyl})_2$, $-\text{C}(=\text{O})\text{OH}$, $-\text{C}(=\text{O})\text{OC}_{1-4}\text{alkyl}$, $-(\text{CH}_2)_r\text{OH}$,
and $-(\text{CH}_2)_r\text{OC}_{1-4}\text{alkyl}$;
 R_f , at each occurrence, is independently selected from H, F, Cl, Br, CN, OH, C_{1-5} alkyl
optionally substituted with OH, C_{3-6} cycloalkyl, and phenyl;


p, at each occurrence, is independently selected from zero, 1, and 2; and
r, at each occurrence, is independently selected from zero, 1, 2, 3, and 4.

3. The compound according to claim 2 of Formula (II):



(II)


or a pharmaceutically acceptable salt thereof, wherein:





R₂ is selected from CH₃, CH₂CH₃ and -CH₂-cyclopropyl substituted with 0-2 F, Cl, and CH₃;

R₃ is selected from H, F, and -OC₁₋₄ alkyl;

R₄ is selected from








R_5 , at each occurrence, is independently selected from H, F, Cl, Br, CN, =O, C_{1-4} alkyl substituted with 0-4 R_e , $-(CH_2)_rOR_b$, $-(CH_2)_rS(O)_pR_c$, $-S(O)_pNR_aR_a$, $-(CH_2)_rNR_aS(O)_pR_c$, $-(CH_2)_rNR_aR_a$, $-(CH_2)_rNR_aC(=O)R_b$, $-NR_aC(=O)OR_b$, $-NR_aC(=O)NR_aR_a$, $-(CH_2)_rC(=O)R_b$, $-(CH_2)_rC(=O)OR_b$, $-(CH_2)_rC(=O)NR_aR_a$, $-(CH_2)_rOC(=O)R_b$, $-(CH_2)_rOC(=O)OR_b$, $-(CH_2)_rO(CH_2)_rC(=O)NR_aR_a$, C_{3-6} cycloalkyl substituted with 0-4 R_e , aryl substituted with 0-4 R_e , and heterocyclyl substituted with 0-4 R_e ;

R_6 , at each occurrence, is independently selected from H, C_{1-3} alkyl substituted with 0-4 R_e , $-S(O)_pR_c$, $-C(=O)R_b$, $-(CH_2)_rC(=O)OR_b$, $-(CH_2)_rC(=O)NR_aR_a$, $-$


$C(=O)(CH_2)_rNR_aC(=O)R_b$, $-S(O)_pNR_aR_a$, aryl substituted with 0-4 R_e , and heterocyclyl substituted with 0-4 R_e ;
 R_a , at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e , C_{2-6} alkenyl substituted with 0-5 R_e , C_{2-6} alkynyl substituted with 0-5 R_e , $-(CH_2)_r-C_{3-10}$ carbocyclyl substituted with 0-5 R_e , and $-(CH_2)_r$ -heterocyclyl substituted with 0-5 R_e ; or R_a and R_a together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 0-5 R_e ;
 R_b , at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e , C_{2-6} alkenyl substituted with 0-5 R_e , $-(CH_2)_r-C_{2-6}$ alkynyl substituted with 0-5 R_e , $-(CH_2)_r-C_{3-10}$ carbocyclyl substituted with 0-5 R_e , and $-(CH_2)_r$ -heterocyclyl substituted with 0-5 R_e ;
 R_c , at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_e , C_{2-6} alkenyl substituted with 0-5 R_e , C_{2-6} alkynyl substituted with 0-5 R_e , $-(CH_2)_r-C_{3-6}$ carbocyclyl substituted with 0-5 R_e , and $-(CH_2)_r$ -heterocyclyl substituted with 0-5 R_e ;
 R_d , at each occurrence, is independently selected from H and C_{1-6} alkyl substituted with 0-5 R_e ;
 R_e , at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_f , C_{2-6} alkenyl, C_{2-6} alkynyl, $-(CH_2)_r-C_{3-6}$ cycloalkyl, $-(CH_2)_r$ -aryl, $-(CH_2)_r$ -heterocyclyl, F, Cl, Br, CN, NO_2 , =O, $-NH_2$, $-NHC_{1-4}$ alkyl, $-N(C_{1-4}$ alkyl) $_2$, $-C(=O)OH$, $-C(=O)OC_{1-4}$ alkyl, $-(CH_2)_rOH$, and $-(CH_2)_rOC_{1-4}$ alkyl;
 R_f , at each occurrence, is independently selected from H, F, Cl, Br, CN, OH, C_{1-5} alkyl optionally substituted with OH, C_{3-6} cycloalkyl, and phenyl;
 p , at each occurrence, is independently selected from zero, 1, and 2; and
 r , at each occurrence, is independently selected from zero, 1, 2, 3, and 4.

4. The compound according to claim 3 of Formula (III):



(III)

or a pharmaceutically acceptable salt thereof, wherein:



R_2 is $-\text{CH}_2\text{-cyclopropyl}$;

R_3 is $-\text{OC}_{1-4}$ alkyl;

R_5 , at each occurrence, is independently selected from H, F, Cl, Br, CN, C_{1-4} alkyl substituted with 0-4

R_e , $-(\text{CHR}_d)_r\text{OR}_b$, $-(\text{CH}_2)_r\text{S}(\text{O})_p\text{R}_c$, $-\text{S}(\text{O})_p\text{NR}_a\text{R}_a$, $-(\text{CH}_2)_r\text{NHS}(\text{O})_p\text{R}_c$, $-(\text{CH}_2)_r\text{NR}_a\text{R}_a$, $-(\text{CH}_2)_r\text{NHC}(=\text{O})\text{R}_b$, $-\text{NHC}(=\text{O})\text{OR}_b$, $-(\text{CHR}_d)_r\text{C}(=\text{O})\text{NR}_a\text{R}_a$, $-(\text{CH}_2)_r\text{C}(=\text{O})\text{OR}_b$, $-\text{OC}(=\text{O})\text{OR}_b$, $-\text{O}(\text{CH}_2)_{0-1}\text{C}(=\text{O})\text{NR}_a\text{R}_a$, C_{3-6} cycloalkyl substituted with 0-4 R_e , aryl substituted with 0-4 R_e , and heterocyclyl substituted with 0-4 R_e ;

R_a , at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e , C_{2-6} alkenyl substituted with 0-5 R_e , C_{2-6} alkynyl substituted with 0-5 R_e , $-(\text{CH}_2)_r\text{-C}_{3-10}$ carbocyclyl substituted with 0-5 R_e , and $-(\text{CH}_2)_r\text{-heterocyclyl}$ substituted with 0-5 R_e ; or R_a and R_a together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 0-5 R_e ;

R_b , at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e , C_{2-6} alkenyl substituted with 0-5 R_e , $-(\text{CH}_2)_r\text{-C}_{2-6}$ alkynyl substituted with 0-5 R_e , $-(\text{CH}_2)_r\text{-C}_{3-10}$ carbocyclyl substituted with 0-5 R_e , and $-(\text{CH}_2)_r\text{-heterocyclyl}$ substituted with 0-5 R_e ;

R_c , at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_e , C_{2-6} alkenyl substituted with 0-5 R_e , C_{2-6} alkynyl substituted with 0-5 R_e , $-(\text{CH}_2)_r\text{-}$

C₃₋₆ carbocyclyl substituted with 0-5 R_e, and -(CH₂)_r-heterocyclyl substituted with 0-5 R_e;

R_d, at each occurrence, is independently selected from H, C₁₋₄ alkyl, and OH;

R_e, at each occurrence, is independently selected from C₁₋₆ alkyl substituted with 0-5 R_f, C₂₋₆ alkenyl, C₂₋₆ alkynyl, -(CH₂)_r-C₃₋₆ cycloalkyl, -(CH₂)_r-aryl, -(CH₂)_r-heterocyclyl, F, Cl, Br, CN, NO₂, =O, -NH₂, -NHC₁₋₄alkyl, -N(C₁₋₄alkyl)₂, -C(=O)OH, -C(=O)OC₁₋₄alkyl, -(CH₂)_rOH, -(CH₂)_rOC₁₋₄alkyl, and SO₂C₁₋₄alkyl;

R_f, at each occurrence, is independently selected from H, F, Cl, Br, CN, OH, C₁₋₅ alkyl optionally substituted with OH, C₃₋₆ cycloalkyl, and phenyl;


p, at each occurrence, is independently selected from zero, 1, and 2; and

r, at each occurrence, is independently selected from zero, 1, 2, 3, and 4.

5. The compound according to claim 4, or a pharmaceutically acceptable salt thereof, wherein:

R₃ is -OCH₃;


R₅, at each occurrence, is independently selected from H, F, Cl, Br, CN, C₁₋₄alkyl, -(CH₂)₀₋₁OR_b, -S(O)₂NH₂, -NHS(O)₂C₁₋₃ alkyl, -NHS(O)₂C₂₋₄alkenyl, -NHC(=O)R_b



R_b, at each occurrence, is independently selected from H and C₁₋₆ alkyl substituted with 0-5 R_e,


R_e, at each occurrence, is independently selected from C₁₋₆ alkyl, F, Cl, Br, CN, NO₂, =O, -NH₂, -NHC₁₋₄alkyl, -N(C₁₋₄alkyl)₂, -C(=O)OH, -C(=O)OC₁₋₄alkyl, -(CH₂)_rOH, -(CH₂)_rOC₁₋₄alkyl, and SO₂C₁₋₄alkyl; and
r, at each occurrence, is independently selected from zero and 1.

6. The compound according to claim 3 or a pharmaceutically acceptable salt thereof, wherein:



R_2 is $-\text{CH}_2\text{-cyclopropyl}$;

R_3 is $-\text{OC}_{1-4}$ alkyl;



R_5 , at each occurrence, is independently selected from H, F, Cl, Br, CN, C_{1-4} alkyl

substituted with 0-4 R_e , $-(\text{CH}_2)_r\text{OR}_b$, $-\text{S}(\text{O})_p\text{R}_c$, $-\text{S}(\text{O})_p\text{NR}_a\text{R}_a$, $-(\text{CH}_2)_r\text{NR}_a\text{S}(\text{O})_p\text{R}_c$, $-(\text{CH}_2)_r\text{NR}_a\text{R}_a$, $-(\text{CH}_2)_r\text{NR}_a\text{C}(=\text{O})\text{R}_b$, $-\text{NR}_a\text{C}(=\text{O})\text{OR}_b$, $-\text{NR}_a\text{C}(=\text{O})\text{NR}_a\text{R}_a$, $-(\text{CH}_2)_r\text{C}(=\text{O})\text{R}_b$, $-(\text{CH}_2)_r\text{C}(=\text{O})\text{OR}_b$, $-(\text{CH}_2)_r\text{C}(=\text{O})\text{NR}_a\text{R}_a$, $-(\text{CH}_2)_r\text{OC}(=\text{O})\text{R}_b$, C_{3-6} cycloalkyl substituted with 0-4 R_e , aryl substituted with 0-4 R_e , and heterocyclyl substituted with 0-4 R_e ;

R_a , at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e , C_{2-6} alkenyl substituted with 0-5 R_e , C_{2-6} alkynyl substituted with 0-5 R_e , $-(\text{CH}_2)_r\text{-C}_{3-10}$ carbocyclyl substituted with 0-5 R_e , and $-(\text{CH}_2)_r\text{-heterocyclyl}$ substituted with 0-5 R_e ; or R_a and R_a together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 0-5 R_e ;

R_b , at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e , C_{2-6} alkenyl substituted with 0-5 R_e , $-(\text{CH}_2)_r\text{-C}_{2-6}$ alkynyl substituted with 0-5 R_e , $-(\text{CH}_2)_r\text{-C}_{3-10}$ carbocyclyl substituted with 0-5 R_e , and $-(\text{CH}_2)_r\text{-heterocyclyl}$ substituted with 0-5 R_e ;

R_c , at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_e , C_{2-6} alkenyl substituted with 0-5 R_e , C_{2-6} alkynyl substituted with 0-5 R_e , $-(\text{CH}_2)_r\text{-C}_{3-6}$ carbocyclyl substituted with 0-5 R_e , and $-(\text{CH}_2)_r\text{-heterocyclyl}$ substituted with 0-5 R_e ;

R_e , at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_f , C_{2-6} alkenyl, C_{2-6} alkynyl, $-(\text{CH}_2)_r\text{-C}_{3-6}$ cycloalkyl, $-(\text{CH}_2)_r\text{-aryl}$, F, Cl, Br, CN,

NO₂, =O, -NH₂, -NHC₁₋₄alkyl, -N(C₁₋₄alkyl)₂, -C(=O)OH, -C(=O)OC₁₋₄alkyl, -(CH₂)_rOH, and -(CH₂)_rOC₁₋₄alkyl;

R_f, at each occurrence, is independently selected from H, F, Cl, Br, CN, OH, C₁₋₅ alkyl optionally substituted with OH, C₃₋₆ cycloalkyl, and phenyl;



p, at each occurrence, is independently selected from zero, 1, and 2; and

r, at each occurrence, is independently selected from zero, 1, 2, 3, and 4.

7. The compound according to claim 6, or a pharmaceutically acceptable salt thereof, wherein:




R₃ is -OCH₃;

R₅, at each occurrence, is independently selected from H, F, Cl, Br, C₁₋₄alkyl, -OH, -OC₁₋₃alkyl, -NHS(O)₂C₂₋₄alkenyl, NHC(=O)OC₁₋₄ alkyl, C(=O)NH₂, C(=O)NHC₁₋

₄alkyl, and heterocyclyl selected from  and ; and


R_e, at each occurrence, is independently selected from C₁₋₆ alkyl, F, Cl, Br, CN, NO₂, =O, -NH₂, -NHC₁₋₄alkyl, -N(C₁₋₄alkyl)₂, -C(=O)OH, -C(=O)OC₁₋₄alkyl, -(CH₂)_rOH, -(CH₂)_rOC₁₋₄alkyl, and SO₂C₁₋₄alkyl.


8. The compound according to claim 3 or a pharmaceutically acceptable salt thereof, wherein:

 (R₇)₁₋₄ is selected from  and ;

R₂ is -CH₂-cyclopropyl;

R₃ is -OC₁₋₄ alkyl;






R_5 , at each occurrence, is independently selected from H, F, Cl, Br, CN, C_{1-4} alkyl, $-OR_b$, $-S(O)_pR_c$, $-(CH_2)_rNR_aS(O)_pR_c$, $-(CH_2)_rNR_aR_a$, $-(CH_2)_rNR_aC(=O)R_b$, $-NR_aC(=O)OR_b$, $-C(=O)OR_b$, $C(=O)NR_aR_a$, C_{3-6} cycloalkyl substituted with 0-4 R_e , aryl substituted with 0-4 R_e , and heterocyclyl substituted with 0-4 R_e ;

R_6 , at each occurrence, is independently selected from H, C_{1-3} alkyl substituted with 0-4 R_e , $-S(O)_pR_c$, $-C(=O)R_b$, $-C(=O)OR_b$, $-(CH_2)_rC(=O)NR_aR_a$, $-C(=O)(CH_2)_rNR_aC(=O)R_b$, $-S(O)_pNR_aR_a$, aryl substituted with 0-4 R_e , and heterocyclyl substituted with 0-4 R_e ;

R_a , at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e , C_{2-6} alkenyl substituted with 0-5 R_e , C_{2-6} alkynyl substituted with 0-5 R_e , $-(CH_2)_rC_{3-10}$ carbocyclyl substituted with 0-5 R_e , and $-(CH_2)_r$ -heterocyclyl substituted with 0-5 R_e ; or R_a and R_a together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 0-5 R_e ;


R_b , at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e , C_{2-6} alkenyl substituted with 0-5 R_e , $-(CH_2)_rC_{2-6}$ alkynyl substituted with 0-5 R_e , $-(CH_2)_rC_{3-10}$ carbocyclyl substituted with 0-5 R_e , and $-(CH_2)_r$ -heterocyclyl substituted with 0-5 R_e ;

R_c , at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_e , C_{2-6} alkenyl substituted with 0-5 R_e , C_{2-6} alkynyl substituted with 0-5 R_e , $-(CH_2)_rC_{3-6}$ carbocyclyl substituted with 0-5 R_e , and $-(CH_2)_r$ -heterocyclyl substituted with 0-5 R_e ;





(IV)

or a pharmaceutically acceptable salt thereof, wherein:



R_2 is selected from CH_3 and $-\text{CH}_2\text{-cyclopropyl}$;

R_3 is selected from H, F, and $-\text{OC}_{1-4}$ alkyl;



R_5 , at each occurrence, is independently selected from H, F, Cl, Br, CN,

C_{1-4} alkyl, $-(\text{CH}_2)_r\text{OR}_b$, $-\text{NR}_a\text{S}(\text{O})_p\text{R}_c$, $-\text{NR}_a\text{R}_a$, $-\text{NR}_a\text{C}(=\text{O})\text{R}_b$, -

$\text{NR}_a\text{C}(=\text{O})\text{OR}_b$, $-\text{C}(=\text{O})\text{OR}_b$, $-\text{C}(=\text{O})\text{NR}_a\text{R}_a$, $-\text{NR}_a\text{C}(=\text{O})\text{NR}_a\text{R}_a$, C_{3-6} cycloalkyl

substituted with 0-4 R_e , aryl substituted with 0-4 R_e , and heterocyclyl substituted with 0-4 R_e ;

R_6 , at each occurrence, is independently selected from H and C_{1-3} alkyl;

R_a, at each occurrence, is independently selected from H, C₁₋₆ alkyl substituted with 0-5 R_e, C₂₋₆ alkenyl substituted with 0-5 R_e, C₂₋₆ alkynyl substituted with 0-5 R_e, -(CH₂)_r-C₃₋₁₀carbocyclyl substituted with 0-5 R_e, and -(CH₂)_r-heterocyclyl substituted with 0-5 R_e;

R_b, at each occurrence, is independently selected from H, C₁₋₆ alkyl substituted with 0-5 R_e, C₂₋₆ alkenyl substituted with 0-5 R_e, C₂₋₆ alkynyl substituted with 0-5 R_e, -(CH₂)_r-C₃₋₁₀carbocyclyl substituted with 0-5 R_e, and -(CH₂)_r-heterocyclyl substituted with 0-5 R_e;

R_c, at each occurrence, is independently selected from C₁₋₆ alkyl substituted with 0-5 R_e, C₂₋₆alkenyl substituted with 0-5 R_e, C₂₋₆ alkynyl substituted with 0-5 R_e, -(CH₂)_r-C₃₋₆ carbocyclyl substituted with 0-5 R_e, and -(CH₂)_r-heterocyclyl substituted with 0-5 R_e;

R_d, at each occurrence, is independently selected from H and C₁₋₃ alkyl;

R_e, at each occurrence, is independently selected from C₁₋₆ alkyl substituted with 0-5 R_f, C₂₋₆ alkenyl, C₂₋₆ alkynyl, -(CH₂)_r-C₃₋₆ cycloalkyl, -(CH₂)_r-aryl, F, Cl, Br, CN, NO₂, =O, N(C₁₋₄alkyl)₂, -C(=O)OH, -C(=O)OC₁₋₄alkyl, -(CH₂)_rOH, and -(CH₂)_rOC₁₋₄alkyl;

R_f, at each occurrence, is independently selected from H, F, Cl, Br, CN, OH, C₁₋₅ alkyl optionally substituted with OH, C₃₋₆ cycloalkyl, and phenyl;


p, at each occurrence, is independently selected from zero, 1, and 2; and

r, at each occurrence, is independently selected from zero, 1, 2, 3, and 4.

11. The compound according to claim 10, or a pharmaceutically acceptable salt thereof, wherein:

R₂ is CH₂-cyclopropyl;

R₃ is -OCH₃;



R₅, at each occurrence, is independently selected from H, F, Cl, Br, C₁₋₄alkyl, and -(CH₂)₀₋₁OH; and


R_d is H.

12. The compound according to claim 2 or a pharmaceutically acceptable salt thereof,
wherein:

L is -C(=O)NH-;

R₂ is -CH₂-cyclopropyl;

R₃ is -OC₁₋₄ alkyl;



R₅, at each occurrence, is independently selected from H, F, Cl, Br, C₁₋₄alkyl, -OH, and -CN; and


R₆, at each occurrence, is independently selected from H and C₁₋₃alkyl.

13. The compound according to claim 2 or a pharmaceutically acceptable salt thereof,
wherein:

L is -O-;


R₂ is -CH₂-cyclopropyl;

R₃ is -OC₁₋₄ alkyl;




R₅, at each occurrence, is independently selected from H, F, Cl, Br, C₁₋₄alkyl, -OH, and -CN.

14. The compound according to claim 2 of Formula (VI):





(VI)

or a pharmaceutically acceptable salt thereof, wherein:




R_2 is $-\text{CH}_2\text{-cyclopropyl}$;




R_5 is selected from H, OH, CH_2OH , and $-\text{C}(\text{CH}_3)_2\text{OH}$.

15. The compound according to claim 2 of Formula (VII):




(VII)

or a pharmaceutically acceptable salt thereof, wherein:



R₂ is -CH₂-cyclopropyl;



R₅, at each occurrence, is independently selected from F, Cl, C₁₋₄alkyl, -(CH₂)_rOR_b, -S(O)₂NR_aR_a, -NR_aS(O)₂R_c, and -C(=O)NR_aR_a;

R₆, at each occurrence, is independently selected from H and C₁₋₃alkyl;

R_a, at each occurrence, is independently selected from H and C₁₋₄ alkyl substituted with 0-5 R_e;

R_b, at each occurrence, is independently selected from H and C₁₋₄ alkyl substituted with 0-5 R_e,

R_c, at each occurrence, is independently C₁₋₄ alkyl substituted with 0-5 R_e;

R_e, at each occurrence, is independently selected from F, Cl, Br, -OH, and -OC₁₋₄alkyl;

r, at each occurrence, is independently selected from zero, 1, and 2.

16. A pharmaceutical composition comprising the compound according to claim 1, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

17. The composition according to claim 16, in combination with an additional therapeutic agent.

18. A method of inhibiting PAD4 in a biological sample *in vitro* comprising the step of contacting the PAD4 with a compound according to claim 1.

19. A compound according to claim 1 for use in therapy.

20. Use of a compound according to claim 1 in the manufacture of a medicament for the treatment of a PAD4 mediated disease.